Medrx Co., Ltd.

As of June 30, 2026, Medrx Co., Ltd. carries a market capitalization of 3.31B, placing it among publicly traded companies globally. Its enterprise value stands at 2.17B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Medrx Co., Ltd.'s next confirmed earnings release is scheduled for November 13, 2026.

As of June 30, 2026, Medrx Co., Ltd. has 60.27M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Medrx Co., Ltd. maintains a current ratio of 13.89, meaning it holds 13.9x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Medrx Co., Ltd.'s stock has declined approximately 65.33% over the past 52 weeks. The 50-day moving average sits at 60.56, while the 200-day moving average is 79.68.

These figures are as of June 30, 2026. Total book value stands at 1.59B, with working capital of 1.25B providing operational flexibility.